Evidence-Based Policy Messages™
- Value of Vaccines
- Pharmaceutical Benefit-Risk
- Intellectual Property Protection
- Compulsory Licensing of Pharmaceuticals
The biopharmaceutical industry’s experience shows that clear messages drive business and help meet company objectives. This has been demonstrated in submissions to regulatory agencies, in feature, benefit and risk messages to prescribers and patients, as well as in comprehensive product dossiers and pricing messages provided to payers. The industry excels in creating and managing messages.
Unfortunately, few players – including the biopharmaceutical industry – have developed similar message skills for public policy and government settings. Most messages about health care policy issues today lack simplicity, clarity and evidence-based support and fail to honor the reality of those in policy-making roles.
The need for more effective value messages for all aspects of health care has never been greater. I believe they can be crafted and – if crafted well – will be used by policymakers themselves.
Working with Nancy Bloeser, I developed a set of 32 Evidence-Based MessagesTM on the Value of Vaccines for a global biopharmaceutical company. These messages were designed to be used, individually or in multiples, to present information and address concerns expressed by policy and decision-makers. They became the basis for a variety of collateral materials, including a White Paper, Executive Summary and a peer-review publication in the journal Vaccine co-authored by three of the company’s executives. The government of China, upon seeing the messages, used them to form the first chapter of a three-chapter book on vaccine-preventable disease in China.
I believe that when messages are clear, concise and evidence-based, regardless of their having been developed by any stakeholder viewed as solely self-interested, they will be accepted by governments and others who might otherwise be critics, and will pave the way to a better dialogue about how to better care for the world’s people.